Company intelligence / Profile preview
Apogenix
Heidelberg, Baden-Württemberg, Germanyapogenix.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Lead immunotherapy candidate asunercept is in clinical development for solid tumors, hemato-oncological indications, and viral infections. A phase II trial for COVID-19 patients was conducted in Spain and Russia. Their TRAIL receptor agonist APG880 (ABBV-621/eftozanermin-alpha) is in phase Ib clinical study for multiple myeloma.[1][2]
- Therapeutic areas
- OncologyInfectious DiseasesHematology
- Modalities
- Protein therapeuticsFusion proteinsImmunotherapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AbbVie
Beyond the preview
Go deeper on Apogenix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apogenix.